Literature DB >> 9525481

Constitutive activation of Jak-2 and Tyk-2 in a v-Src-transformed human gallbladder adenocarcinoma cell line.

Y Murakami1, S Nakano, Y Niho, N Hamasaki, K Izuhara.   

Abstract

It is well known that v-Src phosphorylates various substrates on tyrosine residue and associates with tyrosine-phosphorylated proteins as well as proline-rich ligands through its SH2 and SH3 domains, respectively, thereby inducing oncogenic transformation. A signal pathway from the cell surface to genes in the nucleus, the Jak/STAT (signal transducers and activators of transcription) pathway, has been shown to be involved in the signal transduction mechanism mediated by many cytokines and growth factors. Although a member of the STAT family, STAT3 has been reported to be constitutively activated in several v-Src-transformed cells, and it still remains unknown whether Jak molecules, which act upstream of STATs, are involved in the v-Src-induced activation mechanism of STAT3. In this study, we analyzed activations of both Jak and STAT molecules using v-Src-transformed HAG-1 cells derived from a human gallbladder adenocarcinoma. STAT3 was found to be constitutively activated in v-Src-transformed HAG-1 cells, but not in either non-transformed mock-transfected or activated c-H-ras-transfected HAG-1 cells, even though the other known STAT molecules are expressed. Furthermore, both Jak-2 and Tyk-2 were constitutively activated only in v-Src-transformed HAG-1 cells. Association of v-Src with either STAT3 or the Jak molecules was not observed. No change of this activation was detected by either interferon (IFN)-alpha2a or IFN-gamma, which had shown inhibitory effects on the growth of v-Src-transformed HAG-1 cells. These results raise the possibility that Jak-2 and Tyk-2 are both activated by v-Src, thereby contributing to the constitutive activation of STAT3 in the v-Src-transformed cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9525481     DOI: 10.1002/(SICI)1097-4652(199805)175:2<220::AID-JCP12>3.0.CO;2-C

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  7 in total

1.  Expression of Stat3 in feline mammary gland tumours and its relation to histological grade.

Authors:  C Petterino; A Ratto; E Arcicasa; G Podestà; M Drigo; C Pellegrino
Journal:  Vet Res Commun       Date:  2006-08       Impact factor: 2.459

2.  Regulation of Connexin43 Function and Expression by Tyrosine Kinase 2.

Authors:  Hanjun Li; Gaelle Spagnol; Li Zheng; Kelly L Stauch; Paul L Sorgen
Journal:  J Biol Chem       Date:  2016-05-27       Impact factor: 5.157

3.  Glycine-extended gastrin activates two independent tyrosine-kinases in upstream of p85/p110 phosphatidylinositol 3-kinase in human colonic tumour cells.

Authors:  Audrey Ferrand; Aline Kowalski-Chauvel; Julie Pannequin; Claudine Bertrand; Daniel Fourmy; Marlene Dufresne; Catherine Seva
Journal:  World J Gastroenterol       Date:  2006-03-28       Impact factor: 5.742

4.  The inducible nitric-oxide synthase (iNOS)/Src axis mediates Toll-like receptor 3 tyrosine 759 phosphorylation and enhances its signal transduction, leading to interferon-β synthesis in macrophages.

Authors:  Ming-Yu Hsieh; Miao Ying Chang; Yen-Jen Chen; Yung Kuo Li; Tsung-Hsien Chuang; Guann-Yi Yu; Chun Hei Antonio Cheung; Hui-Chen Chen; Ming-Chei Maa; Tzeng-Horng Leu
Journal:  J Biol Chem       Date:  2014-02-13       Impact factor: 5.157

5.  Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2.

Authors:  V Boudny; S Nakano
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

6.  Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.

Authors:  Xing Chen; Yuping Du; Jing Nan; Xinxin Zhang; Xiaodong Qin; Yuxin Wang; Jianwen Hou; Qin Wang; Jinbo Yang
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

7.  Positive feedback regulation between IL10 and EGFR promotes lung cancer formation.

Authors:  Tsung-I Hsu; Yi-Chang Wang; Chia-Yang Hung; Chun-Hui Yu; Wu-Chou Su; Wen-Chang Chang; Jan-Jong Hung
Journal:  Oncotarget       Date:  2016-04-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.